Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Articles online first > Giornale Italiano di Dermatologia e Venereologia 2020 Apr 29

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Giornale Italiano di Dermatologia e Venereologia 2020 Apr 29

DOI: 10.23736/S0392-0488.20.06643-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Tofacitinib for the treatment of psoriasis and psoriatic arthritis

Arvin IGHANI 1, Jorge R. GEORGAKOPOULOS 1, Jensen YEUNG 1, 2, 3, 4

1 Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada; 2 Division of Dermatology, Department of Medicine, Women’s College Hospital, Toronto, ON, Canada; 3 Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 4 Probity Medical Research Inc., Waterloo, ON, Canada


PDF


Tofacitinib is a novel oral janus kinase (JAK) inhibitor approved for the treatment of psoriatic arthritis. It was also investigated for the treatment of plaque psoriasis, although it is not approved by the Food and Drug Administration for this indication. This article aims to summarize the efficacy and safety data of tofacitinib for treatment of psoriatic disease. A comprehensive review of literature was conducted on the PubMed database using the search terms: "((tofacitinib) AND (psoriasis)) OR ((tofacitinib) AND (psoriatic arthritis))". Data from the pivotal clinical trials evaluating tofacitinib in the treatment of psoriatic disease were summarized. The Oral-treatment Psoriasis Trial (OPT) study series demonstrated that tofacitinib is efficacious in the treatment of plaque psoriasis with an acceptable safety profile. The OPT studies also demonstrated the non-inferiority of tofacitinib 10mg twice daily compared to etanercept. The Oral Psoriatic Arthritis triaL (OPAL) study series demonstrated that tofacitinib significantly improved psoriatic arthritis outcomes compared to placebo and had an acceptable safety profile. Its efficacy is comparable to adalimumab in psoriatic arthritis. Patients treated with tofacitinib should be monitored for herpes zoster, malignancies, blood clots, and changes in laboratory values. Overall, tofacitinib is a useful new systemic agent in the treatment of psoriatic disease. Its oral route of administration, novel JAK pathway target, short half-life, and strong recapture rates after treatment interruption make it a unique new tool for psoriatic disease management. Further long-term studies will help determine its role in the treatment algorithm for psoriatic arthritis and its indication for plaque psoriasis.


KEY WORDS: Tofacitinib; Janus kinase inhibitor; JAK inhibitor; Psoriasis; Psoriatic arthritis; Psoriatic disease; Systemic treatment; Oral treatment; Efficacy; Safety; Review

top of page